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The prognosis of human immunodeficiency virus (HIV)
infection has improved in recent years with the introduction
of antiretroviral treatment. While the frequency of
AIDS-defining events has decreased as a cause of death,
mortality from non-AIDS-related events including end-stage
renal diseases has increased. The etiology of chronic
kidney disease is multifactorial: immune-mediated
glomerulonephritis, HIV-associated nephropathy, thrombotic
microangiopathies, and so on. HIV infection is no longer a
contraindication to transplantation and is becoming standard
therapy in most developed countries. The HIV criteria used
to select patients for renal transplantation are similar in
Europe and North America. Current criteria state that prior
opportunistic infections are not a strict exclusion criterion,
but patients must have a CD4þ count above 200 cells/mm3
and a HIV-1 RNA viral load suppressible with treatment. In
recent years, more than 200 renal transplants have been
performed in HIV-infected patients worldwide, and mid-term
patient and graft survival rates have been similar to that of
HIV-negative patients. The main issues in post-transplant
period are pharmacokinetic interactions between
antiretrovirals and immunosuppressants, a high rate of acute
rejection, the management of hepatitis C virus coinfection,
and the high cardiovascular risk after transplantation. More
studies are needed to determine the most appropriate
antiretroviral and immunosuppressive regimens and the
long-term outcome of HIV infection and kidney graft.
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A few years ago, human immunodeficiency virus (HIV)
infection was an absolute contraindication for solid organ
transplantation. Concerns that post-transplant immuno-
suppression could result in accelerated HIV disease and
increased risk for opportunistic infections meant that
HIV-infected patients were not candidates for transplanta-
tion. Since the introduction of combined antiretroviral
treatment (cART) in 1996, the natural history of
HIV-infected patients has changed dramatically. Although
AIDS-defining events have decreased steadily as a cause of
death, there has been an increase in mortality from
non-AIDS-related infections and late-stage organ diseases.1
The first experiences for solid organ transplantation in
HIV-infected patients were liver transplants in patients with
hepatitis C virus (HCV) coinfection and hepatic cirrhosis.2 In
the case of end-stage renal disease (ESRD), renal replacement
therapies (hemodialysis and peritoneal dialysis) are an
alternative to renal transplantation. This is one of the reasons
why renal transplantation was not initially considered a
therapeutic option for HIV-infected patients with ESRD.
However, at present, renal transplantation is a valid option in
adequately selected HIV-infected patients with ESRD under
dialysis or pre-emptively before starting dialysis.3 We present
the state of the art of renal transplantation in HIV-infected
patients, focusing on clinical aspects, therapeutic strategies
(immunosuppressive and antiretroviral treatments), ethical
issues, comorbidity, and challenges that have to be faced in
the coming years.
ETIOLOGY OF KIDNEY DISEASE IN HIV-INFECTED PATIENTS
Nephropathy is a common finding in patients with HIV
infection and can present as acute or chronic kidney disease.
Acute renal failure can be produced by the toxic effects
of antiretroviral therapy (for example, tenofovir, indinavir)
or nephrotoxic antimicrobial agents used in the treatment of
opportunistic infections (for example, aminoglycosides, ampho-
tericin, foscarnet, trimethoprim-sulfamethoxazole, acyclovir).4,5
The etiology of kidney disease is multifactorial: immune-
mediated glomerulonephritis, HIV-associated nephropathy
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(HIVAN), drug-induced renal disease, nonreversible acute
renal failure, or thrombotic microangiopathy. Moreover,
long-term survival and an increase in cART-induced meta-
bolic alterations will possibly cause an increase in diabetes
and hypertensive renal diseases.5
Classic HIVAN presents histologically as collapsing focal
segmental glomerulosclerosis and clinically as severe protei-
nuria, renal failure, and rapid progression to ESRD. It is the
most common cause of ESRD in untreated HIV-infected
black individuals who develop renal disease. It primarily
occurs in patients of African descent, suggesting a genetic
predisposition to the disease. Risk factors for its development
include a CD4þ T-cell count o200 cells/mm3 and a high
HIV-RNA viral load. Characteristic histological findings
include collapsing focal and segmental glomerulosclerosis,
tubular epithelial atrophy with microcystic dilatation of
the tubules, and lymphocytic interstitial infiltration. Viral
infection of renal cells seems to have an important role in
the pathogenesis of HIVAN. Without adequate treatment, the
prognosis of HIVAN is poor. Although there are strong
observational data supporting a role for cART in the
treatment of HIVAN, no prospective, randomized, controlled
trials have been performed to support it. In addition,
performance of a randomized trial in this disorder seems
unlikely, as it generally affects individuals with uncontrolled
HIV infection who require treatment.5–7
ESRD AND RENAL REPLACEMENT THERAPY IN
HIV-INFECTED PATIENTS
The global incidence and prevalence of ESRD in HIV-
infected patients is unknown, with only some information
available in selected cohorts of black individuals.8 Most
studies have focused on chronic kidney disease, although
there is much less information on advanced stages of kidney
disease. A recent EuroSIDA survey revealed a prevalence of
0.46% (95% confidence interval, 0.38–0.54%) among the
HIV-infected population with ESRD in Europe.9
Prevalence of HIV infection in dialysis units in the United
States, Europe, and other regions
Prevalence of HIV infection in dialysis units varies widely
between countries and even within the same country
(Table 1). In the United States, the number of infected
patients has increased during the past decade. In 2002, 1.5%
(range 0.3–1.5%) and 0.4% (range 0.4–0.8%) of patients were
reported to have HIV infection and AIDS, respectively.10
In Europe,11–17 the overall prevalence of HIV infection in
dialysis units was 0–5% in 1980.11 In the early 1990s, the
European Renal Association-Dialysis and Transplant Associa-
tion created a European registry including 152,658 patients
under dialysis; the prevalence of HIV infection was 0.12%.12
In the cART era, information on prevalence in European
countries is scarce, with the exception of small isolated
studies from France14,15 and Spain.16,17
Other than three small-scale studies from the pre-cART
era, there is little information from other world regions.18–20
Survival of HIV-infected patients receiving renal
replacement therapy
Survival of HIV-infected patients receiving dialysis has
increased in the last two decades. Early studies from the
1980s reported that survival in patients with newly diagnosed
AIDS and ESRD initiating hemodialysis was poor. Most
of these patients had advanced HIV disease that was often
accompanied by other opportunistic diseases.21 Outcome
has improved dramatically, and the mortality rate is now
approaching that for ESRD in the general population.22
A recent study reported survival rates at 1, 3, and 5 years for
HIV-infected patients on dialysis of 95.2, 71.7, and 62.7%,
respectively; these were significantly lower than those of a
matched HIV-negative cohort of dialysis patients.23 Different
factors have contributed to improved survival, the most
relevant being the introduction of cART and treatment of
opportunistic infections, as well as enhanced dialysis
procedures. Some predictors of survival have been established
in recent studies. The risk factors for mortality in the HIV-
infected dialysis population are a lower CD4þ T-cell count,
a higher viral load, the absence of cART, and a history of
opportunistic infections.23–25 In addition, underexposure
or inadequate dose adjustment of cART in patients who
have impaired renal function and/or are receiving dialysis
may contribute to excess mortality among HIV-infected
patients.26 Despite this overall improvement in survival in
recent years, a study including cohorts comprising black
individuals reported poor survival in the pre-cARTand in the
cART era, as a consequence of inadequate HIV treatment
in those patients (nearly half of patients initiating dialysis in
the cART era were not receiving antiretroviral drugs).8
HIV-INFECTED PATIENTS ON THE RENAL TRANSPLANT
WAITING LIST
Criteria for including HIV-infected patients on the
transplant waiting list
Most transplant groups from Europe and North America
have been working toward harmonizing criteria for solid
Table 1 | Prevalence of HIV infection in dialysis centers in the
United States, Europe, and other regions
Country (reference) Year
Total number
of patients
on dialysis
Prevalence
of HIV
infection (%)
United States10 1985 ND 0.3
2002 263,820 1.5
Europe11,12 1984–1986 44000 0–5
1990 152,658 0.12
Italy13 1990 21,500 0.11
1995 27,000 0.13
France14,15 1997 22,707 0.36
2002 27,577 0.67
Spain16,17 2004 4962 1.15
2006 14,876 0.54
Egypt18 1991 5000 1.64
Japan19 1986 1314 0
Brazil20 1986 132 14
Abbreviations: HIV, human immunodeficiency virus; ND, no data available.
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organ transplantation in HIV-infected patients.27–31 These
criteria are summarized in Table 2.
K Clinical criteria: Ideally, no patients should have had
AIDS-defining diseases, as this may lead to a greater risk
for reactivation. However, some opportunistic infections
(tuberculosis, esophageal candidiasis, and Pneumocystis
jiroveci pneumonia) have been withdrawn as exclusion
criteria, because they can be treated effectively and
prevented.
K Immunological criteria: All groups have agreed that the
CD4þ T-cell count should be4200 cells/mm3 for renal
transplantation, because most opportunistic infections
appear when the CD4þ T-cell count is below this cutoff.
K Virological criteria: The ideal situation is one in which
the patient tolerates cART before transplant with an
undetectable HIV viral load in plasma by ultrasensitive
techniques (o50 copies/ml). In some cases (for example,
patients who remain viremic with antiretroviral medica-
tion), it is essential to carry out antiretroviral sensitivity
testing to ascertain the real therapeutic options.
Some patients do not have an indication for cART, as
they are long-term non-progressors or do not fulfill the
immunological or clinical criteria to start treatment and,
therefore, have viremia that is detectable in plasma.
In this setting, it is unknown whether and when (pre- or
post-transplant) it would be beneficial to initiate cART,
so that an undetectable viral load can be reached.
K Other criteria: The candidate must have a favorable
psychiatric evaluation. Patients who actively consume
drugs or alcohol will be excluded. In Spain, a consump-
tion-free period of 2 years is recommended for heroin
and cocaine and 6 months for other drugs (for example,
alcohol). Patients who are on stable methadone main-
tenance programs are not excluded. Finally, patients must
show an appropriate degree of social stability to ensure
adequate care in the post-transplant period.
Factors associated with failure to include HIV-infected
kidney transplant candidates on the transplant list
There is less information on the evaluation of HIV-infected
patients for transplantation. The largest study performed
to date retrospectively reviewed 309 potentially eligible
HIV-infected patients who had been evaluated for renal
transplantation. Only 20% were included on the list or
underwent transplant compared with 73% in HIV-negative
patients evaluated during the same period. The most
common factors associated with failure to complete trans-
plant evaluation are: CD4þ T-cell count and viral load data
not provided at initial evaluation (35%), CD4þ T-cell count
and viral load not meeting the eligibility criteria (21%), and
other factors including black race (black HIV-infected
patients seem less likely to complete the transplant evalua-
tion, a pattern that has also been observed in the general
transplant population32) and a history of illicit drug use.33
In Europe, recent data from the EuroSIDA cohort study
evaluated this issue among 88 HIV-infected ESRD patients.
Criteria related to poor control of HIV infection (low CD4þ
T-cell count or detectable viral load) were reported in 30% of
cases and the remaining two-thirds of patients were excluded,
usually because of cardiovascular diseases or diabetes.9
EXPERIENCE IN RENAL TRANSPLANTATION IN
HIV-INFECTED PATIENTS
Experience in the pre-cART era (before 1996)
Between 1980 and 1990, a total of 39 HIV-infected kidney
recipients (case reports and case series with a small number
of patients) were documented (Table 3).34–54 After a mean
follow-up of 48 months (range 8–109), 21 patients died
(53.8%). This early experience was discouraging. Most cases
acquired HIV infection by transplantation or by blood
transfusion or through blood products received during or
shortly after transplantation. Transplant recipients with
untreated or unrecognized HIV infection often had rapid
progression of opportunistic infections and poor outcomes.
The development of a screening test for HIV antibodies in
1984 and its mandatory use before blood and organ donation
since 1985 proved crucial in preventing further spread of
the disease by medical intervention.34
Swanson et al.55 performed a retrospective study of a
historical cohort of 63,210 cadaveric kidney recipients
with valid HIV serology entries in the USRDS (United States
Renal Data System) from 1987 to 1997. At the time of
their procedure, 32 patients (0.05%) were HIV infected. The
5-year patient and graft survival rates were significantly
reduced in HIV-infected recipients (71 and 44%, respec-
tively) in comparison with the USRDS population (78 and
61%, respectively) (Table 4). In the multivariate analysis,
Table 2 | HIV criteria for renal transplantation in Spain, Italy, the United Kingdom, and the United States
Spain29 Italy31 United Kingdom30 United Statesa(ref. 28)
Opportunistic infections Someb None in the
previous year
None after cART-induced
immunological
reconstitution
Somec
Neoplasm No No No
CD4+ T-cell count (cells/mm3) 4200 4200 4200 4200
Plasma HIV-1 RNA viral load BDL on cART Yes Yes Yes Yes
Abbreviations: BDL, below detection level; cART, combined antiretroviral treatment; HIV, human immunodeficiency virus.
aCooperative Clinical Trials in Adult Transplantation criteria.
bPrevious tuberculosis, Pneumocystis jiroveci pneumonia (PCP), or esophageal candidiasis are not exclusion criteria.
cPCP and esophageal candidiasis are not exclusion criteria.
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HIV-positive status was independently associated with
patient mortality and decreased graft survival.
Experience in the cART era (1996–2010)
In the last few years, retrospective studies, case reports, and
small prospective studies have shown more encouraging
results, suggesting that renal transplantation is feasible in
adequately selected HIV-infected patients. Patient survival
and renal allograft survival are similar to those of non-
HIV-infected patients (Table 5).9,56–74
One of the largest and first experiences in renal
transplantation in HIV-infected patients was reported by
Kumar et al.65 and included 40 patients. The 1- and 2-year
patient survival rates were 85 and 82%, and graft survival
rates were 75 and 71%, respectively. Plasma HIV-1 RNA
remained undetectable and CD4þ T-cell counts remained
4400 cells/mm3 with no evidence of AIDS for up to 2 years.
Acute rejection was frequent (22%).
Roland et al.66 describe the preliminary results of a
prospective cohort including 18 kidney transplants followed
over 3 years. Patient survival was 94% and graft survival
was 83%. These results were similar to those of the general
transplant population. The CD4þ T-cell counts and
HIV-RNA levels remained stable. It is important to notice
the high incidence of acute renal rejection at 1 and 3 years (52
and 70%, respectively). In contrast, Gruber et al.67 recently
reported their experience with 8 HIV-infected renal
transplant recipients; the graft and patient survival rates at
1 year were 88 and 100%, respectively, and the acute rejection
rate was 13%.
The results of the largest prospective, nonrandomized trial
of kidney transplantation in HIV-infected patients have
recently been published. A total of 150 HIV-infected kidney
transplant recipients were followed for up to 3 years at 19 US
transplantation centers. The patient and graft survival rates at
3 years were 88.2 and 73.7%, respectively. These rates were
Table 3 | Renal transplantation in the pre-cART period (before 1996)a
Author (reference) Year Number Donor Follow-upb Fatal outcomec
Feduska et al.36 1980 2 Cadaver 44.5 2 (100%)
Kumar et al.37 1982 1 LD 8 1 (100%)
Imbasciati et al.38 1982 1 Cadaver 50 1 (100%)
Milgrom et al.39 1982 1 Cadaver 19 1 (100%)
Lang et al.40 1983 1 Cadaver 17 0
Poli et al.41 1983–1985 8 Cadaver 51 3 (37.5%)
Erice et al.42 1983–1984 2 Cadaver 74.5 0
Prompt et al.43 1984 2 Cadaver 26.5 2 (100%)
L’age-Stehr et al.44 1984 1 Cadaver 74 1 (100%)
Schwartz et al.45 1983–1984 4 Cadaver 69.2 2 (50%)
Margreiter et al.46 1984 1 Cadaver 69 0
Briner et al.47 1984 1 Cadaver 48 1 (100%)
Ahuja et al.48 1984 1 Cadaver 109 1 (100%)
Simonds et al.49 1985 2 Cadaver 23 2 (100%)
Bowen et al.50 1986 1 Cadaver 31 0
Ward et al.51 1986 1 Cadaver 31 0
Kerman et al.52 1987 2 Cadaver 27.5 1 (50%)
Carbone et al.53 1988 2 1 Cadaver/1 LD 31.5 2 (100%)
Tzakis et al.54 1981–1990 5 Cadaver 33 1 (20%)
Global 1980–1990 39 37 Cadaver/2 LD 48 (8–109) 21 (53.8%)
Abbreviations: cART, combined antiretroviral treatment; LD, living donor.
aAdapted from Schwarz et al.34 and Trullas et al.35
bMean time in months.
cNumber (percentage).
Table 4 | Patient and graft survival rates in HIV-positive renal transplant recipients. Differences between pre-cART and cART
era
Pre-cART era, 1987–1997a cART era, 2003–2009b
5-year survival rates 1/3-year survival rates
USRDS (n=63,210) HIV + (n=32) P-value SRTR (age X65)c SRTR (overall)c HIV+ (n=150) P-value
Patient survival 78% 71% o0.05 91.8/79.5% 96.2/90.6% 94.6/88.2% NS
Graft survival 61% 44% o0.05 88.3/74.4% 92.5/82.8% 90.4/73.7% NS
Acute rejection 48.4% 50% — 12.3%d 31/41% — —
Abbreviations: cART, combined antiretroviral treatment; HIV, human immunodeficiency virus; NS, non significant; SRTR, US Scientific Registry of Transplant Recipients;
USRDS, United States Renal Data System.
aSwanson et al.55
bStock et al.74
cSRTR survival estimates for older kidney transplant recipients (age X65 years) and for all kidney transplant recipients.
dSRTR 1-year acute rejection rate (SRTR 3-year acute rejection rate not available).
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generally between the reported rates in the national database
for older kidney-transplant recipients (X65 years of age) and
for all kidney-transplant recipients (Table 4).74
European experience
In Europe, experience on renal transplantation is scarce. The
first report was from Toso et al.,61 who described a combined
kidney–pancreas transplant in an HIV-infected recipient in
Switzerland. This experience was later extended by Mu¨ller
et al.,68 with two kidney and five liver transplants. Ballarin
et al.69 reported the first case of combined kidney–liver
transplant in an HCV/HIV-coinfected patient with hemo-
philia A. However, the first series of renal transplantation in a
European country included 10 transplants performed in
Spain between 2001 and 2004.64 The same authors recently
updated these results comparing the outcome of 20 HIV-
infected kidney recipients with 40 matched HIV-negative
patients and found similar patient survival but worse graft
survival in the HIV-infected group.71
We reported our experience with three HIV-infected
kidney recipients who received thymoglobulin as induction
therapy. Profound lymphocytopenia was observed in the
post-transplant period, but this was not associated with
an increased risk of bacterial or opportunistic infections in
comparison with a control cohort of 23 HIV-negative kidney
recipients.70 Trullas et al.9 reported their experience with 26
HIV-infected patients from the EuroSIDA cohort study who
received a renal transplant between 2000 and 2004; the
survival rate was 100%. Finally, two recent publications have
reported the experience with 34 renal transplants performed
in France.72,73
Acute rejection rate in the cART era
Most studies report a high rate of acute rejection in
comparison with the low rate of acute rejection in non-
HIV-infected renal transplant recipients. There is high
variability between studies, but in some series the rate is
450%. The explanation remains unclear, although immu-
nological, pharmacological, and racial factors seem to have a
role; in any case, it does not seem to affect allograft survival
rates. In the National Institutes of Health trial, the only
variables associated with an increased risk of graft rejection
were the use of a kidney from a deceased donor and the use
of cyclosporine.74 Drug interactions resulting in altered
exposure to immunosuppressants may be associated with
rejection. The use of new antiretrovirals (for example,
raltegravir) with no interactions with calcineurin inhibitors
may contribute to more stable immunosuppressive regimens,
and therefore a lower risk of acute kidney rejection.75
On the other hand, experimental and clinical research
implicates cytokines and chemokines in the process of
transplant rejection. Patients who were homozygous for CC
chemokine receptor 5 (CCR5) with a 32-bp deletion
(CCR5D32) show longer survival than those with other
genotypes. Antiretroviral drugs with new mechanisms
of action, such as the CCR5 inhibitor maraviroc, could have
an important role in avoiding acute rejection in HIV-infected
renal transplant recipients.76,77
Table 5 | Renal transplantation in the cART period (1997–2010)
Author (reference) Year N Donor Follow-upa Acute rejectionb Graft survival Patient survival
Abbott et al.56 1996–2001 47 Cadaver 31 ND 98% 96%
Qiu et al.57 1997–2004 38 ND 60 0 76% 91%
Kuo et al.58 1999–2000 2 ND 6 ND ND 100%
Stock et al.59 2000 6 4 Cadaver/2 LD 10 4 100% 100%
Roland et al.60 2002 26 ND 10 10 (38) 88% 92%
Toso et al.61 2000 1c Cadaver 84 0 100% 100%
Kumar et al.62 2002 12 ND 12 4 (33) 100% 100%
Stock et al.63 2003 10 6 Cadaver/4 LD 16 5 (50) 100% 100%
Mazuecos et al.64 2001–2005 10 Cadaver 16 4 (40) 90% 100%
Kumar et al.65 2001–2004 40 36 Cadaver/4 LD 24 9 (22) 71% 82%
Roland et al.66 2000–2003 18 10 Cadaver/8 LD 36 12 (70) 83% 94%
Gruber et al.67 2004–2007 8 7 Cadaver/1 LD 15 1 88% 100%
Muller et al.68 ND 2 Cadaver 13 1 100% 100%
Ballarin et al.69 2007 1d 1 Cadaver 12 0 100% 100%
Trullas et al.70 2005–2006 3 3 Cadaver 24 2 100% 100%
Mazuecos71 2001–2009 20 ND 38 8 (40) 74% 95%
Trullas et al.9 2000–2004 26e 21 Cadaver/1 LD ND 8 (30) 77% 100%
Billault et al.72 ND 7 Cadaver 12 0 100% 100%
Touzot et al.73 2005–2009 27 25 Cadaver/2 LD 29 4 (15%) 96% 98%
Stock et al.74 2003–2009 150 102 Cadaver/48 LD 20.4 41%f 73.7%g 88.2%g
Abbreviations: cART, combined antiretroviral treatment; LD, living donor; ND, no data available.
aMean time in months.
bNumber (percentage when NX4).
cPancreas–kidney transplant.
dKidney–liver transplant.
eData available for 22 patients.
fCumulative incidence of rejection at 3 years (49 (33%) patients had 67 acute rejection episodes).
gThree-year survival rates.
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SPECIAL CONSIDERATIONS FOR RENAL TRANSPLANTATION
IN HIV-INFECTED PATIENTS
Renal transplantation in HIV-infected patients is a complex
scenario requiring a multidisciplinary approach. Teams
should include nephrologists, urologists, infectious diseases
and HIV specialists, psychologist/psychiatrists, experts on
alcoholism and drug abuse, and social workers. Several issues
should be taken into account when treating HIV-infected
renal transplant recipients.
Antiretroviral therapy in ESRD
In patients with ESRD, appropriate dose reduction is
warranted for antiretrovirals that are eliminated mainly via
the kidney, with additional doses given after hemodialysis
for those drugs that are readily removed by dialysis. There is
little clinical evidence on the dosage of antiretrovirals in
ESRD patients,78–93 but some general recommendations have
been made. A summary of these recommendations is
provided in Table 6. As nucleoside and nucleotide reverse
transcriptase inhibitors (NRTIs) are eliminated mainly by the
kidneys, a reduced dosage is required in patients with
impaired renal function. Over- or under-prescription of these
drugs could lead to toxicity or virological failure, respectively.
Furthermore, because NRTIs are easily removed by dialysis,
they should be administered after dialysis. The exception is
abacavir, which has low urinary excretion, and, therefore, no
requirement for dose adjustment. However, abacavir has
been associated with increased cardiovascular risk, and must
be prescribed with caution in patients with previous
cardiovascular events.79,81 Abacavir should only be adminis-
tered in patients who are HLA-B*5701 negative. On the other
hand, non-nucleoside reverse transcriptase inhibitors
(NNRTIs), protease inhibitors, and fusion inhibitors are
generally metabolized by the liver and excreted into the
urine in low amounts. Doses of NNRTIs, protease inhibitors,
enfuvirtide, and raltegravir do not need to be adjusted in
patients with chronic kidney disease.78–81 For nevirapine, an
additional 200mg dose is indicated following each
dialysis session. Atazanavir boosted with ritonavir should
be applied in patients under dialysis because of the lower
atazanavir concentrations observed in those patients. Dose
adjustment for maraviroc depends on coadministered
drugs.78–93
Based on the information presented above, the ideal cART
for ART-naive patients undergoing dialysis is a regimen
containing abacavir (if the patient has no history of
cardiovascular risk and a plasma RNA viral load of
o100,000 copies/ml)81 or tenofovir and lamivudine/emtrici-
tabine combined with a third drug that can be efavirenz, a
ritonavir-boosted protease inhibitor, or raltegravir. In
patients with effective cART and NRTI side effects, the cART
regimen could be simplified to monotherapy with lopinavir/
ritonavir or darunavir/ritonavir94–96 or a ritonavir-boosted
protease inhibitor with raltegravir. In patients with virologi-
cal failure, rescue treatment should be based on a genotypic
resistance study. When the patient is close to the renal
transplant, and in order to avoid pharmacokinetic drug
interactions with immunosuppressive drugs and renal
toxicity in the graft, we would recommend, if there are no
contraindications, abacavir, lamivudine, and raltegravir as
first choice or efavirenz as an alternative.
Donor issues
In the pre-cART era, all transplant organs for HIV-infected
patients were from cadaveric donors. In recent years, the
number of living donors has increased, and there is no
contraindication for the use of living donors in HIV-infected
patients. The largest experience with 48 living donors has
recently been reported, finding that the use of a graft from a
living donor was protective for graft loss.74 Organ transplan-
tation from HIV-infected kidney donors is contraindicated at
present, but its potential utility has recently been consid-
ered.97 In South Africa, the first organ transplants involving
four HIV-infected recipients who received kidneys from
deceased HIV-infected donors were performed in 2008.98 At
12 months after transplantation, the four recipients had good
renal function, did not have significant graft rejection, and
HIV infection remained well controlled under cART. Organ
transplantation between HIV-infected patients is controver-
sial, because in addition to ethical issues, recipients can
acquire a different and more aggressive HIV strain (for
example, a different clade or recombinant virus or a virus
with a X4 tropism) from the donor, including HIV drug-
resistant strains, leading to superinfection and HIV disease
progression, can acquire other viruses or subclinical infec-
tions and, finally, the graft quality from the HIV donor may
not be optimal because of undetected factors at the time of
screening and donation. In our opinion, these transplants
should not be performed in the Western World in clinical
practice until their efficacy and safety is evaluated in
prospective long-term controlled studies. In countries with
a resource-limited health system, where there is a high
prevalence of HIV in the general population and HIV
infection is an absolute exclusion criterion for access to
dialysis or renal transplantation, the use of HIV-infected
donors would increase the donor pool, thus providing renal
allografts to patients who would otherwise die as a
consequence of ESRD. In these cases, the balance between
justice and equity is more difficult. Such issues should
encourage intense scientific debate, given their ethical,
nephrological, virological, and clinical implications.99
Antiretroviral therapy in renal transplant recipients
The ideal antiretroviral regimen has not been established for
HIV-infected kidney transplant recipients, and general
recommendations for treating HIV-infected patients must
be followed.79–81 However, it is evident that the ideal
therapeutic regimen must be powerful and sustainable and
aim to achieve and maintain continuous viral suppression
and an increased CD4 lymphocyte count. In addition, in
order to preserve renal graft function, while avoiding the
pharmacokinetic interactions with immunosuppressive drugs
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Table 6 | Antiretroviral dosing recommendations in patients with renal impairmenta
Antiretroviral Renal insufficiency HD/CAPD
NRTIs
Abacavir No dosing adjustment is needed No dosing adjustment is needed.
HD: minimally eliminated. Could be dosed independently of HD
session
Didanosine
(enteric-coated)
X60 kg
CrCl X60: 400 mg every 24 h
CrCl 30–59: 200 mg every 24 h
CrClo30: 125 mg every 24 h
HD/CAPD: 125 mg every 24 h. It is not necessary to administer a
supplemental dose after HD
o60 kg
CrCl X60: 250 mg every 24 h
CrCl 10–59: 125 mg every 24 h
CrCl o10: Not suitable for use in patients o60 kg
with CrCl o10 ml/min. An alternate formulation of
didanosine should be used (Videx pediatric powder
for oral solution 75 mg every 24 h)
HD/CAPD: An alternate formulation of didanosine should be
used (Videx pediatric powder for oral solution 75 mg every 24 h)
Emtricitabine Capsules
CrCl X50: 200 mg every 24 h
CrCl 30–49: 200 mg every 48 h
CrCl 15–29: 200 mg every 72 h
CrClo15: 200 mg every 96 h
Oral solution 10 mg/ml. Due to a difference in the
bioavailability of emtricitabine between the hard
capsule and oral solution presentations, 240 mg
emtricitabine administered as the oral solution (24 ml)
should provide similar plasma levels to those
observed after administration of one 200 mg
emtricitabine hard capsule).
CrCl X50: 240 mg (24 ml) every 24 h
CrCl 30–49: 120 (12 ml) mg every 24 h
CrCl 15–29: 80 mg (8 ml) every 24 h
CrClo15: 60 mg (6 ml) every 24 h
Capsules
HD: 200 mg every 96 h, after HD
CAPD: ND
Oral solution (10 mg/ml)
HD: 60 mg (6 ml) every 24 h, after HD
CAPD: ND
Lamivudineb CrCl X50: 150 mg every 12 h or 300 mg every 24 h
CrCl 30–49: 150 mg every 24 h
CrCl 15–29: 100 mg every 24 h (first dose 150 mg)
CrCl 5–14: 50 mg every 24 h (first dose 150 mg)
CrCl o5: 25 mg every 24 h (first dose 50 mg)
HD: 25 mg every 24 h (first dose 50 mg), after HD
Stavudine X60 kg
CrCl X50: 40 mg every 12 h
CrCl 26–49: 20 mg every 12 h
CrCl 10–25: 20 mg every 24 h
CrCl o10: 20 mg every 24 h
HD: 20 mg every 24 h, after HD
o60 kg
CrCl X50: 30 mg every 12 h
CrCl 26–49: 15 mg every 12 h
CrCl 10–25: 15 mg every 24 h
CrCl o10: 15 mg every 24 h
HD: 15 mg every 24 h, after HD
Zidovudine Significantly elevated GZDV (the major metabolite of
zidovudine) plasma concentrations
CrCl 10–50: 250–300 mg every 12 h
CrCl o10: 250–300 mg every 24 h
300 mg every 24 h, after HD
HD and CAPD appeared to have a negligible effect on the
removal of zidovudine, whereas GZDV elimination was
enhanced.
NtA
Tenofovir
disoproxil fumarate
CrCl X50: usual dose
CrCl 30–49: 300 mg every 48 h
CrCl 10–29: 300 mg every 72–96 h (dosing twice a
week)
No dosing recommendations can be given for non-
HD patients with creatinine clearanceo10 ml/min
HD: 300 mg tenofovir disoproxil (as fumarate) may be
administered every 7 days following completion of a HD session
(assuming three HD sessions per week, each ofB4 h duration or
after 12 h cumulative HD)
NNRTI
Efavirenz Usual dose HD: limited data suggest that there is no reason to adjust the
dose
CAPD: pharmacokinetic data of only one patient suggest that
there is no reason to adjust the dose
Nevirapine CrCl X20 ml/min. Usual dose HD: an additional 200 mg dose of nevirapine following each
dialysis treatment is recommended
Table 6 continued on following page
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Table 6 | Continued
Antiretroviral Renal insufficiency HD/CAPD
Etravirine (TMC-125) Usual dose HD/CAPD: as etravirine is highly bound to plasma proteins,
it is unlikely that it will be significantly removed by HD or PD
PI
Amprenavir Usual dose
Because of the potential risk of toxicity from the large
amount of the excipient propylene glycol, Agenerase
oral solution is contraindicated in patients with renal
failure.
HD/CAPD: as amprenavir is highly bound to plasma proteins,
it is unlikely that it will be significantly removed by HD or PD
Atazanavir Usual dose HD/CAPD: as atazanavir is highly bound to plasma proteins, it is
unlikely that it will be significantly removed by HD or PD
HD: consider using atazanavir boosted with ritonavir. Although
ATV was negligibly eliminated by HD (2%), subjects on HD had
substantially lower ATV levels than controls (AUC 42% lower on
HD days, 28% lower on non-HD days). The mechanism for this
effect is not known (limited data). TDM is advised
Darunavir Usual dose HD/CAPD: as darunavir is highly bound to plasma proteins, it is
unlikely that it will be significantly removed by HD or PD
Fosamprenavir Usual dose HD/CAPD: as amprenavir is highly bound to plasma proteins,
it is unlikely that it will be significantly removed by HD or PD
Indinavir Usual dose HD: limited data showed minimal elimination of indinavir during
a dialysis session
Lopinavir/r Usual dose HD: usual dose. In 13 patients who were on HD LPV AUC values
were similar to those obtained in patients with normal renal
function
CAPD: ND. As lopinavir and ritonavir are highly bound to plasma
proteins, it is unlikely that it will be significantly removed by
CAPD.
Nelfinavir Usual dose HD: it is unlikely that it will be significantly removed by HD.
Data from one patient showed no removal of nelfinavir by a 4 h
HD session
CAPD: it is unlikely that it will be significantly removed by PD.
Data from one patient showed dialysate nelfinavir
concentrations below the limit of detection
Ritonavir Usual dose HD/CAPD: as ritonavir is highly bound to plasma proteins,
it is unlikely that it will be significantly removed by HD or PD
Saquinavir Usual dose HD/CAPD: as saquinavir is highly bound to plasma proteins,
it is unlikely that it will be significantly removed by HD or PD
Tipranavir Usual dose HD/CAPD: as tipranavir is highly bound to plasma proteins,
it is unlikely that it will be significantly removed by HD or PD
Fusion inhibitors
Enfuvirtide (T-20) No dosing adjustment is needed HD: usual dose (limited data)
CCR5 co-receptor
antagonists
Maraviroc (UK-427857) No dosing adjustment is needed without potent
CYP3A4 inhibitors or inducers
Postural hypotension may increase the risk for
cardiovascular adverse events in patients receiving
maraviroc who have severe renal impairment or ESRD
(creatinine clearance o30 ml/min). Maraviroc should
not be prescribed for patients with severe renal
impairment who are receiving CYP3A inhibitors or
inducer
HD/CAPD: ND
Integrase inhibitors
Raltegravir (MK-0518) No dosing adjustment is needed ND
Abbreviations: ATV, atazanavir; AUC, area under the plasma concentration time curve; CAPD, continuous ambulatory peritoneal dialysis; CrCl, creatinine clearance;
ESRD, end-stage renal disease; HBV, hepatitis B virus; HCV, hepatitis C virus; HD, hemodialysis; HIV, human immunodeficiency virus; LPV, lopinavir; ND, no data available;
NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NtA, nucleotide reverse transcriptase inhibitor; PD, peritoneal dialysis;
PI, protease inhibitor; TDM, therapeutic drug monitoring.
aAdapted from Spanish GESIDA/National AIDS Plan Recommendations for antiretroviral therapy in HIV-infected adults, January 2008.79
bDose adjustment for HIV-1 and not for HBV.
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and their side effects, the antiretrovirals included in the
regimen should have these two additional properties:
1. Low probability of inducing dyslipidemia, osteopenia/osteo-
porosis, insulin resistance, and renal toxicity (all of which are
side effects of immunosuppressive drugs). Cardiovascular
safety should also be taken into consideration.
2. Avoidance of pharmacokinetic interactions with calcineurin
inhibitors (cyclosporine and tacrolimus) and mammalian
target of rapamycin (m-TOR) inhibitors (sirolimus) that are
metabolized by cytochrome P450.
If there are no contraindications, we recommend abacavir
(or tenofovir as an alternative) and lamivudine/emtricitabine
combined with raltegravir as the first-choice regimen or
efavirenz as an alternative. Recommendations on antiretro-
viral drug combinations in renal transplant recipients
are summarized in Table 7. Finally, frequent viral load
monitoring in the early period after transplantation is
highly recommended, and resistance testing must also be
considered.
Immunosuppression
The antiviral effects of immunosuppressive drugs have been
extensively reviewed elsewhere and are beyond the scope of this
review.100 However, some brief recommendations can be made:
1. Calcineurin inhibitors: There are no studies comparing
the effects of cyclosporine and tacrolimus on the course of
HIV infection. Cyclosporine is been the most frequently
used drug, in the published experience, probably because
of evidence demonstrating its antiretroviral and/or
immunomodulating effects.101 However, the rate of acute
rejection is higher with cyclosporine than with tacroli-
mus.74 In this setting, some centers use tacrolimus as
the ‘first-line’ calcineurin inhibitor.
2. Mycophenolate mofetil: this drug has inhibitory effects on
HIV replication and is synergistic with some NRTIs.102–104
The leukocyte count should be monitored regularly
because of the myelosuppressive effect of the drug.
3. m-TOR inhibitors: Sirolimus does not seem to have a
negative effect on HIV-infected patients, although experi-
ence with this drug remains scarce. In experimental
studies, sirolimus reduces CCR5 levels in CD4þ T cells,
inhibits R5 HIV-1 replication, and increases the antiviral
activity of fusion inhibitors and CCR5 antagonists.105
In addition, its antiproliferative effect can prove useful
in patients with solid organ transplantation-associated
Kaposi sarcoma.106 Leukocyte count monitoring is also
recommended.
4. Basiliximab/daclizumab: These monoclonal anti-interleu-
kin-2 receptor antibodies have been shown to increase
CD4 T-cell counts mainly by expanding their number and
by prolonging their half-lives.107 Clinical experience has
not shown negative effects on HIV-infected patients.
5. Antilymphocyte polyclonal antibodies: The use of these
drugs is controversial. Carter et al.108 reported 11 HIV-
infected renal transplant recipients who received thymo-
globulin for acute rejection or delayed graft function.
Thymoglobulin produced profound and long-lasting
suppression of the CD4þ T-cell count and was associated
with an increased risk of infections requiring hospitaliza-
tion. In contrast, in another small series (three patients),
we observed that CD4þ T-cell thymoglobulin-induced
lymphocytopenia was not associated with increased risk of
infection.70 Stock et al.74 found that patients who received
this therapy had about twice as many serious infections
per follow-up year as patients who did not receive such
therapy. In addition, the risks of death and of graft loss
were marginally higher for patients who received this
induction therapy. The authors recommend restricting
this therapy for patients at very high immunological risk
for rejection.74
6. Monoclonal anti-CD20 antibody: There is a single
experience with one HIV-infected renal transplant reci-
pient who developed an acute humoral rejection that was
successfully treated with rituximab.109
In the pre-cART era, the immunosuppressive regimens
most frequently used were ‘azathioprine-corticosteroids’ and
‘cyclosporine-corticosteroids.’ Schwarz et al.34 reported a
positive association between cyclosporine and improved
outcome in HIV-infected transplant recipients. Subsequent
observations have suggested that cyclosporine may attenuate
the course of HIV infection by inhibition of viral replica-
tion.101 More recent series from the cART era have reported
different immunosuppressive regimens (Table 8), which are
Table 7 | Antiretroviral drug regimens recommended among
HIV-infected renal transplant recipients
1. NRTIs
K A combination of two NRTIs (for example tenofovir plus
emtricitabine or abacavir plus lamivudine) can be used safely in
renal transplant recipients with dose adjusted to renal function.
K Tenofovir should be used with caution and close monitoring of
renal function.
K Abacavir should not be used in recipients receiving a kidney from
an HLA-B57*01-positive donor to avoid the potential risk of
hypersensitivity reaction to abacavir.
2. NNRTIs and protease inhibitors
K Can be used safely in combination with two NRTIs
K Important interactions with immunosuppressive drugs may
appear, mainly with protease inhibitors.
3. Novel classes of antiretrovirals
K Must be considered in combination with NRTIs
K Integrase inhibitors (raltegravir): have no interactions with
immunosuppressive agents at the CYP450 level.
K Entry inhibitors (enfuvirtide (T20)): could be an alternative in
combination with NRTIs, although subcutaneous administration
is a limitation.
K CCR5 co-receptor antagonists (maraviroc): a substrate of CYP450.
Its levels can be modified by inducers or inhibitors. Experimental
studies have suggested that maraviroc could have an important
role as an antirejection drug.
Abbreviations: CCR5, CC chemokine receptor 5; HIV, human immunodeficiency virus;
NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside/nucleotide
reverse transcriptase inhibitor.
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not significantly different from those used in HIV-negative
renal transplant recipients.9,56–74
Drug–drug interactions
Some pharmacological interactions between antiretrovirals
and immunosuppressants may be clinically relevant. Drug
interactions may require dosing modifications to maintain
appropriate drug levels and for this reason it is very
important to perform close therapeutic drug monitoring.
These interactions are summarized in Table 9.110–129
Mycophenolate mofetil is metabolized mainly by glucur-
onidation in the liver. Atazanavir inhibits UDP-glucuronosyl
transferase and, theoretically, leads to an increase in blood
mycophenolate mofetil levels, whereas ritonavir induces
glucuronidation and could reduce blood mycophenolate
mofetil levels. However, clinically important drug–drug
interactions between mycophenolate mofetil and these
antiretroviral agents have not been reported. Mycophenolate
mofetil has inhibitory effects on HIV and is synergistic with
abacavir, didanosine, and tenofovir.102–104,118
Cyclosporine, tacrolimus, and sirolimus are metabolized
in the liver by cytochrome P450 (isoenzyme 3A4). Anti-
retroviral drugs can act as inhibitors or inducers of these
enzymatic systems. When they act as inhibitors (for example,
protease inhibitors), they increase concentrations of the
immunosuppressive drugs, leading to toxicity; therefore,
doses must be markedly reduced. Clinical experience
indicates that patients on protease inhibitors require only
1–2mg of tacrolimus per week to maintain therapeutic
levels.110–112 Stopping the protease inhibitors while taking
calcineurin inhibitors could cause an acute rejection.
On the other hand, when antiretroviral drugs act as enzyme
inducers (for example, NNRTIs), they reduce drug levels
and can trigger rejection. Therefore, doses of immuno-
suppressive drugs must be increased.113 Stopping the
NNRTI while taking calcineurin inhibitors could cause
toxicity.
In one of the largest series published, Frassetto et al.114
recently described the pharmacokinetics and dosing mod-
ifications in 35 patients (20 kidney recipients, 13 liver
recipients, and 2 kidney–liver transplant recipients). Patients
receiving protease inhibitors had marked increases in
cyclosporine, tacrolimus, and sirolimus levels compared with
those on NNRTIs alone or with patients not on antiretroviral
treatment, and it was necessary to reduce the dose or increase
the dosing interval. Patients taking efavirenz required much
higher doses of cyclosporine than those using any other
antiretroviral drug.
In order to avoid these interactions, some researchers have
reported the use of enfuvirtide plus two NRTIs in liver
transplant recipients.115 Theoretically, based on the elimina-
tion pathways, a pharmacokinetic drug–drug interaction with
the new CCR5 antagonist maraviroc is unlikely. Maraviroc is
a substrate of CYP3A4, but it is not an inducer or inhibitor of
CYP3A4. The HIV-1 integrase inhibitor raltegravir offers
important advantages: it has high antiviral potency and no
significant interactions with immunosuppressive agents,
because of its lack of effect on CYP3A4 (raltegravir is
primarily metabolized by the liver via glucuronidation and
not by CYP3A4).116 Tricot et al.75 recently observed no
Table 8 | Immunosuppressive regimens in HIV-infected renal transplant recipients in the cART period
Author (reference) N CyA FK AZA SRL MMF Corticosteroids
Basiliximab/
daclizumab ATG/OKT3
Abbott et al.56 47 30 (68.2) 19 (43.2) 7 (15.9%) — 38 (86.4) — —/22 (46.8%) —
Qiu et al.57 38 20 (52%) 13 (34%) — 14 (36.8%) — — 10 (26.3%)/6 (15%) 4 (10%)/3 (7.9%)
Kuo et al.58 2 Preferreda Preferreda — — — — — —
Stock et al.59 6 Preferreda — — — Preferreda Preferreda — —
Roland et al.60 26 Preferreda — — — Preferreda — — —
Toso et al.61 1 — 1 (100%) — — 1 (100%) 1 (100%) 1 (100%)/— —
Kumar et al.62 12 ND ND ND ND ND ND ND ND
Stock et al.63 10 Preferreda — — — Preferreda Preferreda — —
Mazuecos et al.64 10 — 10 (100%) — — 10 (100%) 10 (100%) — 1 (10%)/—b
Kumar et al.65 40 40 (100%) — — 40 (100%) — 40 (100%) 40 (100%)/— —
Roland et al.66 18 12 (66%) — — 5 (28%) 16 (89%) — 6 (34%)/1 (5.5%) —
Gruber et al.67 8 8 (100%) — — — 8 (100%) 8 (100%) 8 (100%) —
Muller et al.68 2 1 (50%) 1 (50%) — — 2 (100%) 2 (100%) ND ND
Ballarin et al.69 1 1 (100%) — — 1 (100%) — 1 (100%) 1 (100%)/— —
Trullas et al.70 3 — 1 (33%) — 2 (67%) 3 (100%) 3 (300%) — 3 (100%)/—
Trullas et al.9 26c 7 (32%) 15 (68%) 1 (4.5%) — 19 (86%) 19 (86%) 3 (14%)/5 (23%) 5 (23%)/—
Billault et al.72 7 — 7 (100%) — — 7 (100%) 7 (100%) —/7 (100%) —
Touzot et al.73 27 11 (41%) 16 (59%) — — 27 (100%) 27 (100%) 26 (97%)/— 1 (3%)/—
Stock et al.74 150 33 (22%) 99 (66%) — —d 131 (87%) 150 (100%) 76 (51%) 48 (32%)/—
Abbreviations: ATG, thymoglobulin; AZA, azathioprine; Corticosteroids, prednisone; cART, combined antiretroviral treatment; CyA, cyclosporine; FK, tacrolimus; HIV, human
immunodeficiency virus; MMF, mycophenolate mofetil; N, number of transplants; ND, no data available; OKT3, muromonab-CD3; SRL, sirolimus.
aImmunosuppression regimens were based on these drugs, but the exact number of patients is not specified.
bAnti CD-25 was used in 3 patients.
cData available for 22 patients.
dSRL was used in patients with calcineurin inhibitor-associated nephrotoxicity.
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episodes of acute rejection in five raltegravir-treated
HIV-infected renal transplant recipients.
Given the speed with which new antiretroviral drugs
emerge and thus generate previously unknown interactions,
clinicians should regularly consult updated databases on drug
interactions and product information.124–129
HCV coinfection
HCV coinfection is an important issue in settings were
intravenous drug use is the main risk factor for HIV
transmission.
HCV disease progresses more rapidly in HIV-infected
patients and in liver and kidney transplant recipients.
HCV-infected renal transplant recipients (especially those
with active replication) have higher morbidity and mortality
related with infectious and hepatic complications.130 There is
evidence that HCV-infected transplant recipients have a
significantly greater risk of chronic liver disease, proteinuria,
and chronic allograft nephropathy. Furthermore, patients
with viral replication and chronic elevated alanine amino-
transferase levels have an increased risk of death and
graft loss.131
In the absence of severe chronic liver disease, patients on
dialysis with positive HCV RNA in plasma should be
evaluated for anti-HCV treatment with interferon before
transplantation. Between 30 and 50% of patients have
complete remission, and if a reactivation occurs in the
post-transplant period, the clinical course is less severe
when patients have previously received antiviral therapy.
Combination therapy with interferon and ribavirin is not
recommended in patients on dialysis because of the risk of
hemolysis.132 Options for antiviral therapy in the post-
transplant period are limited. Interferon is not recom-
mended, because of the risk of acute renal rejection. There
is less experience with ribavirin in monotherapy. Ribavirin
lowers alanine aminotransferase levels but has no effect on
HCV viral load. The histopathological efficacy of ribavirin
alone in kidney allograft recipients with hepatitis C is
controversial. Some studies have shown ribavirin to be
associated with histological improvement,133 and other
studies have shown no effect of ribavirin with histological
progression.134
Because so many HIV-infected patients with ERSD also
have HCV infection, it is important to determine whether
renal transplantation is effective in these patients. It is
unknown if the outcome of HCV/HIV-coinfected renal
transplant recipients would be worse than for patients
without HIV infection. In addition, there is not enough
experience to assess the efficacy and safety of interferon and/
or ribavirin treatment in HCV/HIV-coinfected transplant
recipients.
Cardiovascular diseases
As the use of cART became widespread, there has been an
increase in the incidence of non-HIV-related diseases in
HIV-infected patients. These include diabetes mellitus,
hypertension, and other cardiovascular diseases, directly
related—in part—with antiretroviral treatment. In addition,
cardiovascular diseases represent the first cause of death in
renal transplant recipients who survive in the long term.135
Therefore, blood pressure and glucose and cholesterol levels
should be closely monitored to improve long-term survival,
not only in the HIV-infected population, but especially in
HIV-infected renal transplant recipients.136
Ethical issues
Organ transplantation in HIV-infected patients has raised
ethical problems that have not yet been completely solved.
However, with growing experience and encouraging results,
most groups agree that HIV-infected patients with ESRD
should be evaluated for inclusion on the renal transplanta-
tion waiting list.137
PANCREAS–KIDNEY TRANSPLANTATION IN HIV-INFECTED
PATIENTS
There is relatively little experience with simultaneous
pancreas–kidney transplantation in HIV-infected patients
with diabetes mellitus. Preliminary experience suggests that
pancreas–kidney transplantations can be performed using the
same criteria as for kidney transplantation. However, there is
a higher risk of procedure-related infectious complica-
tions.61,138,139
THE NEXT STEP
Several issues must be clarified in the coming years, which
are as follows: (1) the most appropriate combination of
immunosuppressive and antiretroviral drugs must be estab-
lished in terms of clinical efficacy, low acute rejection rate,
absence of nephrotoxicity, appropriate safety profile, minimal
pharmacological interactions, and sustained virological
suppression; (2) knowledge of the pathogenesis of acute
rejection should be expanded; (3) the most appropriate
strategy for the management of HCV/HIV-coinfected
patients must be decided; and (4) physicians should be
aware of the clinical course of HIV infection in patients
receiving long-term immunosuppression.
CONCLUSIONS
1. Renal transplantation waiting list: All HIV-infected
patients with ESRD should be considered candidates for
renal transplantation if they meet the HIV inclusion
criteria.
2. Patient and graft survival: There are enough data to affirm
that renal transplantation in adequately selected HIV-
infected patients is a safe procedure in the short and
medium term, with patient and graft survival rates similar
to those of HIV-negative renal transplant recipients.
3. Acute rejection: In comparison with the HIV-negative
population, HIV-infected patients have a high rate of
acute rejection. The use of antiretroviral drugs that do not
react with immunosuppressive drugs may reduce the risk
of acute rejection.
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Table 9 | Drug interactions between antiretroviral agents and immunosuppressive drugsa
Antiretroviral agentsb
NRTI (abacavir, ddI,
FTC, 3TC, d4T, AZT, TDF) NNRTI (NVP, EFV, and etravirine)
PI (APV, ATV, FPV, DRV, IDV, LPV/r, NFV, RTV,
SQV, TPV/r)
CCR5 co-receptor
antagonists (maraviroc)
Integrase inhibitors
(raltegravir)
Azathioprine No drug–drug interactions between azathioprine and antiretroviral agents have been described. Caution is advised when azathioprine is used with other agents affecting
myelopoiesis, including co-trimoxazole.
Basiliximab Basiliximab is an immunoglobulin; therefore no metabolic drug–drug interactions with antiretrovirals are to be expected.
Cyclosporinec,d Theoretically, based on the
elimination pathways, a
pharmacokinetic drug–drug
interaction is unlikely.
As emtricitabine, lamivudine,
and tenofovir are excreted
mainly via the kidneys,
nephrotoxic drugs could impair
its elimination.
Tenofovir: Increased risk of
nephrotoxicity
NNRTI: may require an increase in
CyA dosage.
EFV: some patients needed an initial
CyA dose of 350–450 mg every 12 h,
followed by a maintenance dose of
250–400 mg every 12 h.
NVP: some patients needed an
initial dose of 200–250 mg every
12 h of CyA, followed by a
maintenance dose of 100–175 mg
every 12 h.
TDM of CyA is recommended
Risk of increased drug levels/toxicity of
immunosuppressive drugs. Markedly lower doses
of immunosuppressive drugs may be required.e
With IDV some patients needed an initial CyA
dose of 75–100 mg every 12 h followed by a
maintenance dose of 75 mg every 12 h.
With LPV/r some patients needed an initial dose of
CyA of 25 mg every 12 h followed by a
maintenance dose of 25 mg every 24–48 h.
With NFV some patients needed an initial dose of
CyA of 50–75 mg every 12 h, followed by a
maintenance dose of 25 mg every 12 h.
In the study by Guaraldi et al.117 (including 12
patients who underwent liver transplantation), the
mean fold decrease in the dosage of
immunosuppressive drug (CyA, FK, SRL) that was
necessary to maintain therapeutic windows was
8.75 (range 8–14) after initiating boosted PIs, and
3 (range 2–4) after initiating unboosted PIs.
TPV/r concentrations of cyclosporine
cannot be predicted, due to conflicting
effect on CYP3A (inhibition) and P-gp
(significant inhibition after the first dose,
but slight induction at steady state). TDM of
CyA is recommendede
Theoretically, based on the
elimination pathways, it is
unlikely that maraviroc
could modify blood CyA
levelsd
Theoretically, based on
the elimination
pathways, a
pharmacokinetic
drug–drug interaction is
unlikely
Daclizumab Daclizumab is an immunoglobulin; therefore, no metabolic drug–drug interactions with antiretrovirals are to be expected.
Everolimusc,d Theoretically, based on the
elimination pathways, a
pharmacokinetic drug–drug
interaction is unlikely
Inducers of CYP3A4 like NNRTI may
increase the metabolism of
everolimus and decrease blood
everolimus levels.
TDM of everolimus is
recommended
Moderate inhibitors of CYP3A4 and P-gp such as
PIs may increase everolimus blood levels
With TPV/r, concentrations of everolimus cannot
be predicted, due to the conflicting effect on
CYP3A (inhibition) and P-gp (slight induction at
steady state)
TDM of everolimus is recommended
Theoretically, based on the
elimination pathways, it is
unlikely that maraviroc
could modify blood
everolimus levelsd
Theoretically, based on
the elimination
pathways, a
pharmacokinetic
drug–drug interaction is
unlikely
Methylprednisolone Theoretically, based on the
elimination pathways, a
pharmacokinetic drug–drug
interaction is unlikely
Theoretically, inducers of CYP3A4
such as NNRTI may increase the
metabolism of corticosteroids and
decrease blood levels
Theoretically, inhibitors of CYP3A4 like PIs may
decrease the metabolism of corticosteroids and
increase blood levels (iatrogenic Cushing’s
syndrome has been described as a result of an
interaction between ritonavir and inhaled
fluticasone)
Theoretically, based on the
elimination pathways, a
pharmacokinetic drug–drug
interaction is unlikely
Theoretically, based on
the elimination
pathways, a
pharmacokinetic
drug–drug interaction is
unlikely
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4. Course of HIV infection: Immunosuppressive therapy
does not have a negative impact on the course of HIV
infection, with no evidence of progression to AIDS and no
further opportunistic infections or neoplasms. Patients
should follow the same prophylaxis protocols as the non-
HIV-infected population.
5. Immunosuppression: The best immunosuppressive regi-
men in HIV-infected renal transplant recipients has not
been completely established. Until results from larger and
controlled studies are available, immunosuppressive therapy
in the early post-transplant period should include induction
therapy with anti-interleukin-2 receptor monoclonal anti-
bodies (basiliximab) in combination with triple therapy
based on calcineurin inhibitors (cyclosporine or tacroli-
mus), mycophenolate mofetil, and corticosteroids. There is
little experience with sirolimus, but it does not seem to have
negative effects. The use of antilymphocyte polyclonal
antibodies is not contraindicated, but produces deep and
persistent lymphocytopenia that must be closely monitored.
This treatment is not recommended in patients with high
viral replication or previous lymphocytopenia.
6. Antiretroviral regimens: Dose adjustment is mandatory for
some antiretroviral drugs. Physicians must be aware of
interactions between immunosuppressive agents and anti-
retroviral drugs, especially protease inhibitors and, to a lesser
extent NNRTIs. For this reason, it is very important to
closely monitor immunosuppressive drugs and, when
possible, antiretroviral drugs (NRTIs, protease inhibitors,
and raltegravir). Antiretroviral regimens containing drugs
with a low pharmacological interaction profile (for example,
raltegravir plus two NRTIs) are recommended.
7. HCV coinfection: There is little experience in the
management and outcome of HCV/HIV-coinfected
patients in the pre- and post-transplant period.
8. Multidisciplinary management: Evaluation and pre- and
post-transplant management should include interdisci-
plinary teams comprising nephrologists, urologists,
infectious diseases and HIV specialists, psychologists,
social workers, and members of alcohol and other drug
detoxification programs.
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